137 related articles for article (PubMed ID: 30262326)
1. Pelvic exenterations for gynecologic cancers: A retrospective analysis of a 30-year experience in a cancer center.
Knight S; Lambaudie E; Sabiani L; Mokart D; Provansal M; Tallet A; Houvenaeghel G
Eur J Surg Oncol; 2018 Dec; 44(12):1929-1934. PubMed ID: 30262326
[TBL] [Abstract][Full Text] [Related]
2. Long-term outcomes of pelvic exenterations for gynecological malignancies: a single-center retrospective cohort study.
Yu JH; Tong CJ; Huang QD; Ye YL; Chen G; Li H; Wen YS; Yang F; Luo NB; Xu GY; Xiong Y
BMC Cancer; 2024 Jan; 24(1):88. PubMed ID: 38229045
[TBL] [Abstract][Full Text] [Related]
3. Influence of tumor size on outcomes following pelvic exenteration.
Smith B; Jones EL; Kitano M; Gleisner AL; Lyell NJ; Cheng G; McCarter MD; Abdel-Misih S; Backes FJ
Gynecol Oncol; 2017 Nov; 147(2):345-350. PubMed ID: 28822555
[TBL] [Abstract][Full Text] [Related]
4. Pelvic Exenteration in Advanced Gynecologic Malignancies - Who Will Benefit?
Egger EK; Liesenfeld H; Stope MB; Recker F; Döser A; Könsgen D; Marinova M; Hilbert T; Exner D; Ellinger J; Mustea A
Anticancer Res; 2021 Jun; 41(6):3037-3043. PubMed ID: 34083295
[TBL] [Abstract][Full Text] [Related]
5. Pelvic exenterations for gynecological malignancies: a study of 36 cases.
Kaur M; Joniau S; D'Hoore A; Van Calster B; Van Limbergen E; Leunen K; Penninckx F; Van Poppel H; Amant F; Vergote I
Int J Gynecol Cancer; 2012 Jun; 22(5):889-96. PubMed ID: 22617477
[TBL] [Abstract][Full Text] [Related]
6. Minimally invasive pelvic exenteration for gynaecological malignancy: A single-centre case series and review of the literature.
Karkia R; Tailor A; Ellis P; Madhuri T; Scala A; Read J; Perry M; Patil K; Blackburn A; Butler-Manuel S; Chatterjee J
Eur J Obstet Gynecol Reprod Biol; 2022 Jul; 274():56-61. PubMed ID: 35584578
[TBL] [Abstract][Full Text] [Related]
7. Pelvic exenteration for recurrent gynecologic malignancy: a study of 28 consecutive patients at a single institution.
Jäger L; Nilsson PJ; Rådestad AF
Int J Gynecol Cancer; 2013 May; 23(4):755-62. PubMed ID: 23407096
[TBL] [Abstract][Full Text] [Related]
8. Curative pelvic exenteration: initial experience and clinical outcome.
Ali Uraiqat A; Al Nsour D; Mestareehy KM; Allababdeh MS; Naffa MTF; Alrabee MM; Al-Hammouri F
Pan Afr Med J; 2023; 44():170. PubMed ID: 37455871
[TBL] [Abstract][Full Text] [Related]
9. Pelvic exenteration for gynecologic malignancies: Postoperative complications and oncologic outcomes.
Romeo A; Gonzalez MI; Jaunarena J; Zubieta ME; Favre G; Tejerizo JC
Actas Urol Esp (Engl Ed); 2018 Mar; 42(2):121-125. PubMed ID: 28911880
[TBL] [Abstract][Full Text] [Related]
10. Pelvic Exenteration in Gynecologic Cancer: La Paz University Hospital Experience.
Moreno-Palacios E; Diestro MD; De Santiago J; Hernández A; Zapardiel I
Int J Gynecol Cancer; 2015 Jul; 25(6):1109-14. PubMed ID: 25853383
[TBL] [Abstract][Full Text] [Related]
11. Pelvic exenteration for recurrent gynecologic malignancy: survival and morbidity analysis of the 45-year experience at UCLA.
Berek JS; Howe C; Lagasse LD; Hacker NF
Gynecol Oncol; 2005 Oct; 99(1):153-9. PubMed ID: 16054678
[TBL] [Abstract][Full Text] [Related]
12. Pelvic exenteration for recurrent or persistent gynecologic malignancies: Clinical and histopathologic factors predicting recurrence and survival in a modern cohort.
Straubhar AM; Chi AJ; Zhou QC; Iasonos A; Filippova OT; Leitao MM; Awowole IO; Abu-Rustum NR; Broach VA; Jewell EL; Sandhu JS; Sonoda Y
Gynecol Oncol; 2021 Nov; 163(2):294-298. PubMed ID: 34518053
[TBL] [Abstract][Full Text] [Related]
13. [Pelvic exenteration--our experience].
Nedialkov K; Magunska N; Bechev B
Akush Ginekol (Sofiia); 2015; 54(9):19-23. PubMed ID: 26863791
[TBL] [Abstract][Full Text] [Related]
14. Quality of life after pelvic exenteration for gynecologic cancer: Findings from a qualitative study.
Nelson AM; Albizu-Jacob A; Fenech AL; Chon HS; Wenham RM; Donovan KA
Psychooncology; 2018 Oct; 27(10):2357-2362. PubMed ID: 29956389
[TBL] [Abstract][Full Text] [Related]
15. Pelvic exenteration: surgical aspects and analysis of early and late morbidity in a series of 106 patients.
De Wever I
Acta Chir Belg; 2011; 111(5):273-81. PubMed ID: 22191127
[TBL] [Abstract][Full Text] [Related]
16. Major complications of urinary diversion after pelvic exenteration for gynecologic malignancies: a 23-year mono-institutional experience in 124 patients.
Houvenaeghel G; Moutardier V; Karsenty G; Bladou F; Lelong B; Buttarelli M; Delpero JR
Gynecol Oncol; 2004 Feb; 92(2):680-3. PubMed ID: 14766266
[TBL] [Abstract][Full Text] [Related]
17. Pelvic exenteration as ultimate ratio for gynecologic cancers: single-center analyses of 37 cases.
de Gregorio N; de Gregorio A; Ebner F; Friedl TWP; Huober J; Hefty R; Wittau M; Janni W; Widschwendter P
Arch Gynecol Obstet; 2019 Jul; 300(1):161-168. PubMed ID: 31011878
[TBL] [Abstract][Full Text] [Related]
18. Pelvic exenteration for gynecologic malignancies: The experience of a tertiary center from Greece.
Haidopoulos D; Pergialiotis V; Aggelou K; Thomakos N; Alexakis N; Stamatakis E; Rodolakis A
Surg Oncol; 2022 Mar; 40():101702. PubMed ID: 35065392
[TBL] [Abstract][Full Text] [Related]
19. Major complications following exenteration in cases of pelvic malignancy: a 10-year experience.
Wydra D; Emerich J; Sawicki S; Ciach K; Marciniak A
World J Gastroenterol; 2006 Feb; 12(7):1115-9. PubMed ID: 16534855
[TBL] [Abstract][Full Text] [Related]
20. Pelvic Exenteration as Potential Cure and Symptom Relief in Advanced and Recurrent Gynaecological Cancer.
Soeda S; Furukawa S; Sato T; Ueda M; Kamo N; Endo Y; Kojima M; Nomura S; Kataoka M; Fujita S; Endo H; Takahashi T; Watanabe T; Yamada H; Fujimori K
Anticancer Res; 2019 Oct; 39(10):5631-5637. PubMed ID: 31570460
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
